GlassScriptPhysician profile
Sadia Cheema
NPI 1144873043
$4,958.15
in general payments reported to CMS, 2019-2025
29 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $128 · 2023: $764 · 2024: $1,398 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178 · Education: $21.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.26 |
| Education | $21.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $872.76 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $621.94 | 2023-2025 | Caplyta |
| Indivior INC. | $387.76 | 2021-2025 | Sublocade |
| Lundbeck LLC | $346.77 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $338.37 | 2021-2024 | Epclusa |
| Alkermes, INC. | $279.07 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $249.16 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $244.14 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $217.80 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $198.71 | 2023-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $148.58 | 2023-2025 | Azstarys |
| Axsome Therapeutics, INC. | $131.91 | 2023-2025 | Auvelity |
| Braeburn INC. | $129.86 | 2023-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $124.71 | 2024-2025 | Cobenfy |
| Orexo US, INC. | $114.76 | 2021-2025 | Zubsolv |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $78.21 | 2024-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $72.02 | 2025 | Trintellix |
| Tris Pharma INC | $48.32 | 2025 | Dyanavel Xr |
| Lilly USA, LLC | $46.40 | 2021 | |
| Amgen INC. | $44.27 | 2021 | |
| Global Blood Therapeutics, INC. | $42.76 | 2021 | |
| Eisai INC. | $42.73 | 2021 | |
| Merck Sharp & Dohme LLC | $37.06 | 2021-2022 | |
| Novo Nordisk INC | $34.26 | 2021 | |
| Janssen Biotech, INC. | $32.73 | 2021 | |
| Tempus Ai, INC | $25.92 | 2024 | Tempus Pixel |
| Medtronic, INC. | $19.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadia Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.